447 related articles for article (PubMed ID: 36241228)
21. Prognostic influence of pre-operative C-reactive protein in node-negative breast cancer patients.
Sicking I; Edlund K; Wesbuer E; Weyer V; Battista MJ; Lebrecht A; Solbach C; Grinberg M; Lotz J; Hoffmann G; Rahnenführer J; Hengstler JG; Schmidt M
PLoS One; 2014; 9(10):e111306. PubMed ID: 25340395
[TBL] [Abstract][Full Text] [Related]
22. Clinicopathological features and prognostic analysis of HER2 low and fibrotic focus in HER2-negative breast cancer.
Yue M; Wu S; Liu C; Cai L; Wang X; Jia Y; Han D; Liu Y
Breast Cancer Res Treat; 2024 Jan; 203(2):373-381. PubMed ID: 37843776
[TBL] [Abstract][Full Text] [Related]
23. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
[TBL] [Abstract][Full Text] [Related]
24. Ki67 as Proliferative Marker in Patients with Early Breast Cancer and Its Association with Clinicopathological Factors.
de Gregorio A; Friedl TWP; Hering E; Widschwendter P; de Gregorio N; Bekes I; Janni W; Dayan D; Huober JB
Oncology; 2021; 99(12):780-789. PubMed ID: 34535596
[TBL] [Abstract][Full Text] [Related]
25. Association between pathological characteristics and recurrence score by OncotypeDX in resected T1-3 and N0-1 breast cancer: a real-life experience of a North Hungarian regional center.
Deme D; Tamaskovics BF; Jammoul N; Kovács S; Kayode EO; Grice JW; Telekes A
Pathol Oncol Res; 2024; 30():1611735. PubMed ID: 38689824
[No Abstract] [Full Text] [Related]
26. Development and validation of an extended Cox prognostic model for patients with ER/PR+ and HER2- breast cancer: a retrospective cohort study.
Xie Y; Li X; Wu Y; Cui W; Liu Y
World J Surg Oncol; 2022 Oct; 20(1):338. PubMed ID: 36224558
[TBL] [Abstract][Full Text] [Related]
27. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
29. [An analysis of 68 invasive lobular breast cancer cases in clinicopathological characteristics and the prognostic determinants].
Liu Q; Xiang HY; Ye JM; Xu L; Zhang H; Zhang S; Duan XN; Liu YH
Zhonghua Wai Ke Za Zhi; 2018 Feb; 56(2):119-123. PubMed ID: 29397625
[No Abstract] [Full Text] [Related]
30. Prognostic significance of estrogen, progesterone and HER2 receptors' status conversion following neoadjuvant chemotherapy in patients with locally advanced breast cancer: Results from a tertiary Cancer Center in Saudi Arabia.
Al-Saleh K; Salah T; Arafah M; Husain S; Al-Rikabi A; Abd El-Aziz N
PLoS One; 2021; 16(3):e0247802. PubMed ID: 33667252
[TBL] [Abstract][Full Text] [Related]
31. Potential roles of lymphovascular space invasion based on tumor characteristics provide important prognostic information in T1 tumors with ER and HER2 positive breast cancer.
Zhao Y; Yang N; Wang X; Huang Y; Zhou X; Zhang D
Clin Transl Oncol; 2020 Dec; 22(12):2275-2285. PubMed ID: 32447641
[TBL] [Abstract][Full Text] [Related]
32. Correlation between Ki67 and histological grade in breast cancer patients treated with preoperative chemotherapy.
Petric M; Martinez S; Acevedo F; Oddo D; Artigas R; Camus M; Sanchez C
Asian Pac J Cancer Prev; 2014; 15(23):10277-80. PubMed ID: 25556461
[TBL] [Abstract][Full Text] [Related]
33. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer.
Curigliano G; Viale G; Bagnardi V; Fumagalli L; Locatelli M; Rotmensz N; Ghisini R; Colleoni M; Munzone E; Veronesi P; Zurrida S; Nolè F; Goldhirsch A
J Clin Oncol; 2009 Dec; 27(34):5693-9. PubMed ID: 19884553
[TBL] [Abstract][Full Text] [Related]
34. Impact of FOXA1 expression on the prognosis of patients with hormone receptor-positive breast cancer.
Hisamatsu Y; Tokunaga E; Yamashita N; Akiyoshi S; Okada S; Nakashima Y; Aishima S; Morita M; Kakeji Y; Maehara Y
Ann Surg Oncol; 2012 Apr; 19(4):1145-52. PubMed ID: 21984487
[TBL] [Abstract][Full Text] [Related]
35. The clinical value of progesterone receptor expression in luminal breast cancer: A study of a large cohort with long-term follow-up.
Lashen AG; Toss MS; Mongan NP; Green AR; Rakha EA
Cancer; 2023 Apr; 129(8):1183-1194. PubMed ID: 36653923
[TBL] [Abstract][Full Text] [Related]
36. TIF1γ interferes with TGFβ1/SMAD4 signaling to promote poor outcome in operable breast cancer patients.
Kassem L; Deygas M; Fattet L; Lopez J; Goulvent T; Lavergne E; Chabaud S; Carrabin N; Chopin N; Bachelot T; Gillet G; Treilleux I; Rimokh R
BMC Cancer; 2015 Jun; 15():453. PubMed ID: 26040677
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of different molecular typing methods and immune status based on RNA sequencing in HR-positive and HER2-negative early-stage breast cancer.
Ren X; Song Y; Zhang Y; Wu H; Chen L; Pang J; Zhou L; Shen S; Liang Z
BMC Cancer; 2022 May; 22(1):548. PubMed ID: 35568835
[TBL] [Abstract][Full Text] [Related]
38. Risk factors for recurrence in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer in Japan: a systematic literature review and meta-analysis.
Miyazaki N; Iwasaki T; Sakai H; Watanuki R; Tanizawa Y; Cai Z; Kawaguchi T; Tsurutani J; Nagashima K
Curr Med Res Opin; 2024 May; 40(5):827-837. PubMed ID: 38597173
[TBL] [Abstract][Full Text] [Related]
39. Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study.
Puig-Vives M; Sánchez MJ; Sánchez-Cantalejo J; Torrella-Ramos A; Martos C; Ardanaz E; Chirlaque MD; Perucha J; Díaz JM; Mateos A; Machón M; Marcos-Gragera R
Gynecol Oncol; 2013 Sep; 130(3):609-14. PubMed ID: 23747837
[TBL] [Abstract][Full Text] [Related]
40. Impact of GATA-3 and FOXA1 expression in patients with hormone receptor-positive/HER2-negative breast cancer.
Hisamatsu Y; Tokunaga E; Yamashita N; Akiyoshi S; Okada S; Nakashima Y; Taketani K; Aishima S; Oda Y; Morita M; Maehara Y
Breast Cancer; 2015 Sep; 22(5):520-8. PubMed ID: 24415069
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
